Skip Navigation
United States Flag

An official website of the United States government. Here's how you know >

A New Look for HHS-OIG. Learn More >>

Change Font Size

OIG Online Portfolio: Drug Pricing and Payment

This Online Portfolio pulls together the Office of Inspector General's (OIG) body of work, including enforcement actions, reports, recommendations and more, as it relates to the drug pricing and payment. The portfolio will be updated periodically.

Impact

Introductory text— note, goal is to highlight OIG’s impact in the area of drug pricing and payment. Text should focus on recommendations and other things that show impact (such as Congressional testimony). Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse dictum urna non ante porta, id dignissim lectus volutpat. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Vivamus non massa sodales tellus euismod dapibus at nec ipsum. Nulla facilisi. Nullam consequat erat nec nunc feugiat, id rutrum leo semper. Donec venenatis, augue vitae placerat tempor, magna lacus sagittis enim, eu pellentesque diam tortor dignissim enim. Nam justo ante, rhoncus quis neque sed, eleifend mattis dui. Cras hendrerit dolor quis malesuada pretium. Nullam mauris turpis, lobortis eu porttitor eu, sodales ac orci. Suspendisse non risus fringilla, venenatis mauris sit amet, convallis metus.

Unimplemented Recommendations

Recommendation Report
CMS should cooperate with industry stakeholder efforts to identify a solution to prevent coupons from being used to purchase drugs paid for by Part D. Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs (OEI-05-12-00540)
CMS should finalize the implementation of automated ASP-related procedures by using AMP-related processes as a model, and subsequently require all manufacturers to submit ASPs through the automated system. Limitations in Manufacturer Reporting of ASP Data for Part B Drugs

Page last updated: December 13, 2016

Portfolio Navigation

Choose a Portfolio

Office of Inspector General, U.S. Department of Health and Human Services | 330 Independence Avenue, SW, Washington, DC 20201